Table 4.
Distributions of NAT2-haplotypes in TB patients with and without adverse effect
|
Hepatotoxicity |
Skin rash |
Eosinophilia |
|||||||||||||
| Haplotype | Present (%) | Absent (%) | OR | 95% CI | P | Present (%) | Absent (%) | OR | 95% CI | P | Present (%) | Absent (%) | OR | 95% CI | P |
| NAT2*4 | 16 (44.4) | 120 (73.2) | 0.265 | 0.129-0.546 | < 0.001 | 34 (68.0) | 102 (68.0) | 1.00 | 0.503-1.987 | 1.000 | 45 (66.2) | 91 (68.9) | 0.880 | 0.472-1.642 | 0.688 |
| NAT2*6A | 14 (38.9) | 29 (17.7) | 3.535 | 1.648-7.585 | 0.001 | 12 (24.0) | 31 (20.7) | 1.22 | 0.570-2.607 | 0.609 | 15 (22.0) | 28 (21.2) | 1.052 | 0.517-2.138 | 0.889 |
| NAT2*7B | 6 (16.7) | 15 (9.1) | 2.235 | 0.818-6.104 | 0.117 | 4 (8.0) | 17 (11.3) | 0.70 | 0.226-2.170 | 0.537 | 8 (11.8) | 13 (9.9) | 1.227 | 0.482-3.124 | 0.667 |
| Total number | 36 | 164 | 50 | 150 | 68 | 132 | |||||||||